Skip to main content
Top
Published in: Tumor Biology 12/2016

01-12-2016 | Original Article

Chloroquine inhibits tumor growth and angiogenesis in malignant pleural effusion

Authors: Qian Li, Dong-mei Yuan, Li-hong Ma, Chen-hui Ma, Ya-fang Liu, Tang-feng Lv, Yong Song

Published in: Tumor Biology | Issue 12/2016

Login to get access

Abstract

Malignant pleural effusion (MPE) is associated with a poor prognosis in lung cancer. Currently, no effective cure exists for MPE. Chloroquine (CQ) has been demonstrated to induce vascular normalization and inhibit tumor growth. The aim of this study was to assess whether CQ affects MPE. The xenografts mice were divided into normal saline (NS), CQ, or bevacizumab (BE) group. Tumor growth and microvascular density (MVD) were monitored. We explored the effect of CQ on the proliferation, survival, and proangiogenic signaling of tumor cells in vitro. We further evaluated the effects of CQ on the viability, migration, and tube formation of human umbilical vein endothelial cells (HUVECs). A chicken chorioallantoic membrane (CAM) model was used to elucidate the effects of CQ on angiogenesis. Finally, an MPE mouse model were treated by CQ, BE, or NS. The volume of pleural effusion, tumor foci, and MVD was evaluated. CQ therapy group exhibited decreased tumor volume, tumor weight, and MVD in the mouse xenografts. CQ inhibited the proliferation of the tumor cells. However, the expression of vascular endothelial growth factor was not affected. Additionally, CQ inhibited the proliferation, migration, and tube formation of HUVECs and also restrained angiogenesis in the CAM. Western blot showed that CQ might suppress angiogenesis by downregulating p-Akt, Jagged1, and Ang2 in HUVECs. In MPE mice, the volume of the pleural effusion, the number of pleural tumor foci, and the MVD were significantly reduced in the CQ group. Our work demonstrated that CQ played the role of an efficient treatment for MPE.
Literature
1.
go back to reference Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008;83:235–50.CrossRefPubMed Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008;83:235–50.CrossRefPubMed
2.
go back to reference Stathopoulos GT. Translational advances in pleural malignancies. Respirology (Carlton, Vic). 2011;16:53–63.CrossRef Stathopoulos GT. Translational advances in pleural malignancies. Respirology (Carlton, Vic). 2011;16:53–63.CrossRef
3.
go back to reference Haas AR, Sterman DH. Novel intrapleural therapies for malignant diseases. Respiration; International Review of Thoracic Diseases. 2012;83:277–92.CrossRefPubMed Haas AR, Sterman DH. Novel intrapleural therapies for malignant diseases. Respiration; International Review of Thoracic Diseases. 2012;83:277–92.CrossRefPubMed
4.
go back to reference Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186:487–92.CrossRefPubMed Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186:487–92.CrossRefPubMed
5.
go back to reference Spella M, Giannou AD, Stathopoulos GT. Switching off malignant pleural effusion formation-fantasy or future? Journal of Thoracic Disease. 2015;7:1009–20.PubMedPubMedCentral Spella M, Giannou AD, Stathopoulos GT. Switching off malignant pleural effusion formation-fantasy or future? Journal of Thoracic Disease. 2015;7:1009–20.PubMedPubMedCentral
6.
go back to reference Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157:1893–903.CrossRefPubMedPubMedCentral Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157:1893–903.CrossRefPubMedPubMedCentral
7.
go back to reference Pichelmayer O, Gruenberger B, Zielinski C, Raderer M. Bevacizumab is active in malignant effusion. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2006;17:1853.CrossRef Pichelmayer O, Gruenberger B, Zielinski C, Raderer M. Bevacizumab is active in malignant effusion. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2006;17:1853.CrossRef
8.
go back to reference Massarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, Mino B, Wistuba II, Faiz SA, Bashoura L, Eapen GA, Morice RC, Jack Lee J, Hong WK, Herbst RS, Jimenez CA. Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. Clinical Lung Cancer. 2014;15:379–86.CrossRefPubMedPubMedCentral Massarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, Mino B, Wistuba II, Faiz SA, Bashoura L, Eapen GA, Morice RC, Jack Lee J, Hong WK, Herbst RS, Jimenez CA. Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. Clinical Lung Cancer. 2014;15:379–86.CrossRefPubMedPubMedCentral
9.
go back to reference Homewood CA, Warhurst DC, Peters W, Baggaley VC. Lysosomes, ph and the anti-malarial action of chloroquine. Nature. 1972;235:50–2.CrossRefPubMed Homewood CA, Warhurst DC, Peters W, Baggaley VC. Lysosomes, ph and the anti-malarial action of chloroquine. Nature. 1972;235:50–2.CrossRefPubMed
10.
go back to reference Zhang Y, Liao Z, Zhang LJ, Xiao HT. The utility of chloroquine in cancer therapy. Curr Med Res Opin. 2015;31:1009–13.CrossRefPubMed Zhang Y, Liao Z, Zhang LJ, Xiao HT. The utility of chloroquine in cancer therapy. Curr Med Res Opin. 2015;31:1009–13.CrossRefPubMed
11.
go back to reference Vezmar M, Georges E. Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol. 2000;59:1245–52.CrossRefPubMed Vezmar M, Georges E. Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol. 2000;59:1245–52.CrossRefPubMed
12.
13.
go back to reference Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol. 2009;625:220–33.CrossRefPubMed Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol. 2009;625:220–33.CrossRefPubMed
14.
go back to reference Kim EL, Wustenberg R, Rubsam A, Schmitz-Salue C, Warnecke G, Bucker EM, Pettkus N, Speidel D, Rohde V, Schulz-Schaeffer W, Deppert W, Giese A. Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro-Oncology. 2010;12:389–400.CrossRefPubMedPubMedCentral Kim EL, Wustenberg R, Rubsam A, Schmitz-Salue C, Warnecke G, Bucker EM, Pettkus N, Speidel D, Rohde V, Schulz-Schaeffer W, Deppert W, Giese A. Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro-Oncology. 2010;12:389–400.CrossRefPubMedPubMedCentral
15.
go back to reference Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34.CrossRefPubMed Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34.CrossRefPubMed
16.
go back to reference Lesiak A, Narbutt J, Kobos J, Kordek R, Sysa-Jedrzejowska A, Norval M, Wozniacka A. Systematic administration of chloroquine in discoid lupus erythematosus reduces skin lesions via inhibition of angiogenesis. Clin Exp Dermatol. 2009;34:570–5.CrossRefPubMed Lesiak A, Narbutt J, Kobos J, Kordek R, Sysa-Jedrzejowska A, Norval M, Wozniacka A. Systematic administration of chloroquine in discoid lupus erythematosus reduces skin lesions via inhibition of angiogenesis. Clin Exp Dermatol. 2009;34:570–5.CrossRefPubMed
17.
go back to reference Grimaldi A, Balestrieri ML, D’Onofrio N, Di Domenico G, Nocera C, Lamberti M, Tonini G, Zoccoli A, Santini D, Caraglia M, Pantano F. The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrence. PLoS One. 2013;8:e79658.CrossRefPubMedPubMedCentral Grimaldi A, Balestrieri ML, D’Onofrio N, Di Domenico G, Nocera C, Lamberti M, Tonini G, Zoccoli A, Santini D, Caraglia M, Pantano F. The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrence. PLoS One. 2013;8:e79658.CrossRefPubMedPubMedCentral
18.
go back to reference Potvin F, Petitclerc E, Marceau F, Poubelle PE. Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. Journal of Immunology (Baltimore, Md: 1950). 1997;158:1872–9. Potvin F, Petitclerc E, Marceau F, Poubelle PE. Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. Journal of Immunology (Baltimore, Md: 1950). 1997;158:1872–9.
19.
go back to reference Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, Vinckier S, Vankelecom H, Garmyn M, Vion AC, Radtke F, Boulanger C, Gerhardt H, Dejana E, Dewerchin M, Ghesquiere B, Annaert W, Agostinis P, Carmeliet P. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell. 2014;26:190–206.CrossRefPubMed Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, Vinckier S, Vankelecom H, Garmyn M, Vion AC, Radtke F, Boulanger C, Gerhardt H, Dejana E, Dewerchin M, Ghesquiere B, Annaert W, Agostinis P, Carmeliet P. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell. 2014;26:190–206.CrossRefPubMed
20.
go back to reference Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146:873–87.CrossRefPubMed Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146:873–87.CrossRefPubMed
21.
go back to reference Takanami I. Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis. Oncol Rep. 2004;12:849–53.PubMed Takanami I. Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis. Oncol Rep. 2004;12:849–53.PubMed
22.
go back to reference Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. The Lancet Oncology. 2010;11:373–82.CrossRefPubMed Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. The Lancet Oncology. 2010;11:373–82.CrossRefPubMed
23.
go back to reference Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM, Noel A. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2002;16:1802–4. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM, Noel A. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2002;16:1802–4.
25.
go back to reference Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nature Reviews Cancer. 2008;8:309–16.CrossRefPubMed Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nature Reviews Cancer. 2008;8:309–16.CrossRefPubMed
26.
go back to reference YL H, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, Aghi MK. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 2012;72:1773–83.CrossRef YL H, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, Aghi MK. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 2012;72:1773–83.CrossRef
27.
go back to reference Mazure NM, Pouyssegur J. Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol. 2010;22:177–80.CrossRefPubMed Mazure NM, Pouyssegur J. Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol. 2010;22:177–80.CrossRefPubMed
28.
go back to reference Cooke VG, LeBleu VS, Keskin D, Khan Z, O’Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, Sugimoto H, Rocha RM, Damascena A, Brentani RR, Kalluri R. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 2012;21:66–81.CrossRefPubMedPubMedCentral Cooke VG, LeBleu VS, Keskin D, Khan Z, O’Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, Sugimoto H, Rocha RM, Damascena A, Brentani RR, Kalluri R. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 2012;21:66–81.CrossRefPubMedPubMedCentral
29.
go back to reference Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10:417–27.CrossRefPubMed Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10:417–27.CrossRefPubMed
30.
go back to reference Giannou AD, Marazioti A, Spella M, Kanellakis NI, Apostolopoulou H, Psallidas I, Prijovich ZM, Vreka M, Zazara DE, Lilis I, Papaleonidopoulos V, Kairi CA, Patmanidi AL, Giopanou I, Spiropoulou N, Harokopos V, Aidinis V, Spyratos D, Teliousi S, Papadaki H, Taraviras S, Snyder LA, Eickelberg O, Kardamakis D, Iwakura Y, Feyerabend TB, Rodewald HR, Kalomenidis I, Blackwell TS, Agalioti T, Stathopoulos GT. Mast cells mediate malignant pleural effusion formation. J Clin Invest. 2015;125:2317–34.CrossRefPubMedPubMedCentral Giannou AD, Marazioti A, Spella M, Kanellakis NI, Apostolopoulou H, Psallidas I, Prijovich ZM, Vreka M, Zazara DE, Lilis I, Papaleonidopoulos V, Kairi CA, Patmanidi AL, Giopanou I, Spiropoulou N, Harokopos V, Aidinis V, Spyratos D, Teliousi S, Papadaki H, Taraviras S, Snyder LA, Eickelberg O, Kardamakis D, Iwakura Y, Feyerabend TB, Rodewald HR, Kalomenidis I, Blackwell TS, Agalioti T, Stathopoulos GT. Mast cells mediate malignant pleural effusion formation. J Clin Invest. 2015;125:2317–34.CrossRefPubMedPubMedCentral
31.
go back to reference Lin H, Tong ZH, Xu QQ, Wu XZ, Wang XJ, Jin XG, Ma WL, Cheng X, Zhou Q, Shi HZ. Interplay of th1 and th17 cells in murine models of malignant pleural effusion. Am J Respir Crit Care Med. 2014;189:697–706.CrossRefPubMed Lin H, Tong ZH, Xu QQ, Wu XZ, Wang XJ, Jin XG, Ma WL, Cheng X, Zhou Q, Shi HZ. Interplay of th1 and th17 cells in murine models of malignant pleural effusion. Am J Respir Crit Care Med. 2014;189:697–706.CrossRefPubMed
Metadata
Title
Chloroquine inhibits tumor growth and angiogenesis in malignant pleural effusion
Authors
Qian Li
Dong-mei Yuan
Li-hong Ma
Chen-hui Ma
Ya-fang Liu
Tang-feng Lv
Yong Song
Publication date
01-12-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5441-z

Other articles of this Issue 12/2016

Tumor Biology 12/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine